TABLE 5.
Pharmacokinetic parameters following intravenous and oral administration in mice for each of AD01, PhX6 and DpNEt.
| Compound | t1/2 h | Tmax h | Cmax µM | Vd L/kg | CL mL/min/kg | AUC0-∞ min∙µmol/L | BA % |
|---|---|---|---|---|---|---|---|
| Intravenous | |||||||
| AD01 | 2.51 ± 0.07 | - | - | 16.24 ± 1.73 | 74.41 ± 6.68 | 186 ± 15 | - |
| PhX6 | 7.96 ± 0.73 | - | - | 14.92 ± 2.09 | 21.47 ± 1.76 | 540 ± 44 | - |
| DpNEt | 1.12 ± 0.13 | - | - | 1.00 ± 0.16 | 10.20 ± 0.93 | 1795 ± 198 | - |
| Oral | |||||||
| AD01 | - | 0.88 ± 0.13 | 0.25 ± 0.05 | - | - | 101 ± 19 | 15 ± 4 |
| PhX6 | |||||||
| - | 0.80 ± 0.12 | 3.45 ± 0.68 | - | - | 1,150 ± 216 | 60 ± 12 | |
| DpNEt | - | 0.70 ± 0.12 | 6.32 ± 1.15 | - | - | 550 ± 148 | 8 ± 2 |